On Wednesday, AstraZeneca Plc AZN launched high-level outcomes from a deliberate interim evaluation of the SERENA-6 Section 3 trial.
SERENA-6 is evaluating the efficacy and security of camizestrant together with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) versus therapy with an AI (anastrozole or letrozole) together with a CDK4/6 inhibitor for HR-positive, HER2-negative superior breast most cancers whose tumors have an emergent ESR1 mutation.
Additionally Learn: Amid Mounting Stress In China, AstraZeneca Buys FibroGen’s Chinese language Unit For $160 Million
The info confirmed that the camizestrant mixture regime demonstrated a statistically important and clinically significant enchancment within the progression-free survival (PFS) endpoint.
The important thing secondary endpoints of time-to-second illness development (PFS2) and general survival (OS) had been immature on the time of this interim evaluation.
Nevertheless, the camizestrant mixture demonstrated a development towards enchancment in PFS2. The security profile of camizestrant together with palbociclib, ribociclib or abemaciclib in SERENA-6 was in line with the identified security profile of every drugs.
No new security issues had been recognized, and discontinuations had been very low and related in each arms.
Earlier this month, AstraZeneca shared outcomes from a post-hoc exploratory subgroup evaluation from the NIAGARA Section 3 trial.
The research confirmed that Imfinzi (durvalumab), administered perioperatively together with neoadjuvant (earlier than surgical procedure) chemotherapy, demonstrated enhancements in event-free survival and general survival versus neoadjuvant chemotherapy with radical cystectomy alone in sufferers with or with no pathologic full response in muscle-invasive bladder most cancers.
Value Motion: AZN inventory is up 0.68% at $75.93 on the final examine on Wednesday.
Learn Subsequent
Picture by Robert Manner through Shutterstock
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
